Table 4. Early response prediction for CML.

Study	n	Baseline	3 Months	6 Months	12 Months	End point
Baseline
Hasford et al.19	1303					OS
Hasford et al.113	2060	High risk				CCyR
Fabarius et al.118	1151	Major route ACA				OS
Response
Hanfstein et al.115	692		MR 10%, MCyR	MR 1%, CCyR		OS
Hughes et al.87	476			MR 10%	MR 1%	EFS
Hehlmann et al.97	1014				MMR, MR 1%	OS
Jabbour et al.55	435		MCyR	CCyR		OS
Marin et al.116	282		MR 9.84%	MR 1.67%	MR 0.53%	OS
Baccarani et al.42	NA		CHR		CCyR	OS
Mahon et al.117	116		CHR			MCyR

Abbreviations: ACA, additional cytogenetic abnormalities; CCyR, complete cytogenetic response; CHR, complete hematological response; CML, chronic myeloid leukemia; EFS, event-free survival; MCyR, major cytogenetic response; MMR, major molecular response; MR, molecular response; NA, not available; OS, overall survival.

Percentages are according to the International Scale.